Mary Chapman, features writer —

Some 20 U.S. organizations with a focus on amyotrophic lateral sclerosis (ALS) have put their names on a letter that seeks to help shape Congressional funding priorities for the federal legislative fiscal year 2025 to better serve the ALS community. The correspondence from the nonprofits, sent last week, was…

An unprecedented $58 million donation to the ALS Association is a “beacon of hope” for the amyotrophic lateral sclerosis (ALS) community and will finance treatment centers, aid to financially strapped patients, and clinical trials of promising treatments, according to the U.S.-based nonprofit. The donation from the estate…

To reflect a new era of commitment and determination in the fight against amyotrophic lateral sclerosis (ALS), The ALS Association Greater New York Chapter has become ALS United Greater New York. The rebranding of the New York City-based nonprofit represents a break…

An initiative at a University of Illinois campus that aims to improve voice recognition software for people with speech difficulties is recruiting adults in the U.S. and Puerto Rico living with amyotrophic lateral sclerosis (ALS). Known as the Speech Accessibility Project, it is led by the Urbana-Champaign…

LifeArc, a U.K.-based independent medical research charity, is offering £5 million (about $6 million) to scientists around the world as part of a grant program to tackle motor neuron disease (MND) using repurposed or combined medicines. The program is part of the Motor Neuron Disease Translational Challenge, which…

Two Canadian provinces — Prince Edward Island, and Newfoundland and Labrador — are covering the cost of the oral formulation of Radicava (edaravone) for eligible residents with amyotrophic lateral sclerosis (ALS). Patients will have access through their provincial drug plans to Radicava Oral Suspension, developed along with…

The biotechnology company ProJenX recently received $15 million in funding to advance its experimental oral treatment prosetin for amyotrophic lateral sclerosis (ALS). This Series A financing round is essentially the next round of funding after seed money was used to rapidly develop the investigational treatment. Both rounds…

Is it feasible to remotely collect health data from people with amyotrophic lateral sclerosis (ALS)? And would doing so help in gauging disease progression among patients? That’s what a remote observational study called ALS Go-Digital is now trying to assess. If validated, the approach could pave the way to…

Continuing its annual support, BluSky Restoration Contractors has raised $140,000 to advance research at the Miller Laboratory at Washington University School of Medicine in St. Louis, Missouri, for new and better amyotrophic lateral sclerosis (ALS) treatments. The funds were raised through the sixth annual Rakers Classic…

Cytokinetics is calling for proposals from patient advocacy organizations focused on amyotrophic lateral sclerosis (ALS) and cardiovascular conditions for its 6th annual Communications Grant Program. The 2024 program will award five grants totaling $20,000 each to groups serving the ALS, heart failure, and hypertrophic cardiomyopathy communities. These…